argenx SE (ARGX)
NASDAQ: ARGX · Real-Time Price · USD
792.32
-7.68 (-0.96%)
Oct 6, 2025, 1:18 PM EDT - Market open
argenx SE Revenue
argenx SE had revenue of $967.19M in the quarter ending June 30, 2025, with 97.62% growth. This brings the company's revenue in the last twelve months to $3.12B, up 88.04% year-over-year. In the year 2024, argenx SE had annual revenue of $2.25B with 77.22% growth.
Revenue (ttm)
$3.12B
Revenue Growth
+88.04%
P/S Ratio
15.61
Revenue / Employee
$1,951,733
Employees
1,599
Market Cap
48.72B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.25B | 979.61M | 77.22% |
Dec 31, 2023 | 1.27B | 827.58M | 187.66% |
Dec 31, 2022 | 441.01M | -87.25M | -16.52% |
Dec 31, 2021 | 528.27M | 466.31M | 752.59% |
Dec 31, 2020 | 61.96M | -30.85M | -33.24% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
ARGX News
- 2 days ago - argenx announces Extraordinary General Meeting of Shareholders on November 18, 2025 - GlobeNewsWire
- 18 days ago - FUJIFILM Biotechnologies Expands Strategic Partnership with argenx to Include U.S. Manufacturing Operations - Business Wire
- 19 days ago - argenx SE - Special Call - Seeking Alpha
- 24 days ago - argenx: Bullish On This R&D Focused Biotech Stock - Seeking Alpha
- 4 weeks ago - Argenx SE (ARGX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 5 weeks ago - argenx to Present at Upcoming Investor Conferences - GlobeNewsWire
- 5 weeks ago - Argenx Immune Disorder Drug's Reach Could Get Much Bigger With Major Trial Win - Benzinga
- 6 weeks ago - argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG - GlobeNewsWire